168 related articles for article (PubMed ID: 38115797)
1. NOTCH3 promotes docetaxel resistance of prostate cancer cells through regulating TUBB3 and MAPK signaling pathway.
Sun X; Zhang Y; Xin S; Jin L; Cao Q; Wang H; Wang K; Liu X; Tang C; Li W; Li Z; Wen X; Yang G; Guo C; Liu Z; Ye L
Cancer Sci; 2024 Feb; 115(2):412-426. PubMed ID: 38115797
[TBL] [Abstract][Full Text] [Related]
2. TUBB3 Reverses Resistance to Docetaxel and Cabazitaxel in Prostate Cancer.
Sekino Y; Han X; Kawaguchi T; Babasaki T; Goto K; Inoue S; Hayashi T; Teishima J; Shiota M; Yasui W; Matsubara A
Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31412591
[TBL] [Abstract][Full Text] [Related]
3. PrLZ increases prostate cancer docetaxel resistance by inhibiting LKB1/AMPK-mediated autophagy.
Zeng J; Liu W; Fan YZ; He DL; Li L
Theranostics; 2018; 8(1):109-123. PubMed ID: 29290796
[No Abstract] [Full Text] [Related]
4. NPRL2 promotes docetaxel chemoresistance in castration resistant prostate cancer cells by regulating autophagy through the mTOR pathway.
Luo S; Shao L; Chen Z; Hu D; Jiang L; Tang W
Exp Cell Res; 2020 May; 390(2):111981. PubMed ID: 32234375
[TBL] [Abstract][Full Text] [Related]
5. Circ_0004087 interaction with SND1 promotes docetaxel resistance in prostate cancer by boosting the mitosis error correction mechanism.
Chen L; Song Y; Hou T; Li X; Cheng L; Li Y; Xing Y
J Exp Clin Cancer Res; 2022 Jun; 41(1):194. PubMed ID: 35659274
[TBL] [Abstract][Full Text] [Related]
6. MiR-129-5p promotes docetaxel resistance in prostate cancer by down-regulating CAMK2N1 expression.
Wu C; Miao C; Tang Q; Zhou X; Xi P; Chang P; Hua L; Ni H
J Cell Mol Med; 2020 Feb; 24(3):2098-2108. PubMed ID: 31876385
[TBL] [Abstract][Full Text] [Related]
7. Use of miR‑145 and testicular nuclear receptor 4 inhibition to reduce chemoresistance to docetaxel in prostate cancer.
Zhu J; Qin P; Cao C; Dai G; Xu L; Yang D
Oncol Rep; 2021 Mar; 45(3):963-974. PubMed ID: 33650661
[TBL] [Abstract][Full Text] [Related]
8. Identification of lipidomic profiles associated with drug-resistant prostate cancer cells.
Ingram LM; Finnerty MC; Mansoura M; Chou CW; Cummings BS
Lipids Health Dis; 2021 Feb; 20(1):15. PubMed ID: 33596934
[TBL] [Abstract][Full Text] [Related]
9. Long noncoding RNA MALAT1 enhances the docetaxel resistance of prostate cancer cells via miR-145-5p-mediated regulation of AKAP12.
Xue D; Lu H; Xu HY; Zhou CX; He XZ
J Cell Mol Med; 2018 Jun; 22(6):3223-3237. PubMed ID: 29633510
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-223-3p regulates cell chemo-sensitivity by targeting FOXO3 in prostatic cancer.
Feng Q; He P; Wang Y
Gene; 2018 Jun; 658():152-158. PubMed ID: 29518547
[TBL] [Abstract][Full Text] [Related]
11. LncRNA NEAT1 promotes docetaxel resistance in prostate cancer by regulating ACSL4 via sponging miR-34a-5p and miR-204-5p.
Jiang X; Guo S; Zhang Y; Zhao Y; Li X; Jia Y; Xu Y; Ma B
Cell Signal; 2020 Jan; 65():109422. PubMed ID: 31672604
[TBL] [Abstract][Full Text] [Related]
12. Glucocorticoid Receptor and β-Catenin Interact in Prostate Cancer Cells and Their Co-Inhibition Attenuates Tumorsphere Formation, Stemness, and Docetaxel Resistance.
Martinez SR; Elix CC; Ochoa PT; Sanchez-Hernandez ES; Alkashgari HR; Ortiz-Hernandez GL; Zhang L; Casiano CA
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108293
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of claspin promotes docetaxel resistance and is associated with prostate-specific antigen recurrence in prostate cancer.
Babasaki T; Sentani K; Sekino Y; Kobayashi G; Thang Pham Q; Katsuya N; Akabane S; Taniyama D; Hayashi T; Shiota M; Oue N; Teishima J; Matsubara A; Yasui W
Cancer Med; 2021 Aug; 10(16):5574-5588. PubMed ID: 34240817
[TBL] [Abstract][Full Text] [Related]
14. EGFR-mediated hyperacetylation of tubulin induced docetaxel resistance by downregulation of HDAC6 and upregulation of MCAK and PLK1 in prostate cancer cells.
Pu YS; Huang CY; Wu HL; Wu JH; Su YF; Yu CR; Lu CY; Wu WJ; Huang SP; Huang YT; Hour TC
Kaohsiung J Med Sci; 2024 Jan; 40(1):23-34. PubMed ID: 37916740
[TBL] [Abstract][Full Text] [Related]
15. Identification of biomarkers, pathways and potential therapeutic target for docetaxel resistant prostate cancer.
Liu RJ; Li SY; Liu LQ; Xu B; Chen M
Bioengineered; 2021 Dec; 12(1):2377-2388. PubMed ID: 34077304
[TBL] [Abstract][Full Text] [Related]
16. Protein Disulfide Isomerase 4 Drives Docetaxel Resistance in Prostate Cancer.
Qian S; Zhang S; Wu Y; Ding Y; ; Li X
Chemotherapy; 2020; 65(5-6):125-133. PubMed ID: 33238278
[TBL] [Abstract][Full Text] [Related]
17. Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy.
Ploussard G; Terry S; Maillé P; Allory Y; Sirab N; Kheuang L; Soyeux P; Nicolaiew N; Coppolani E; Paule B; Salomon L; Culine S; Buttyan R; Vacherot F; de la Taille A
Cancer Res; 2010 Nov; 70(22):9253-64. PubMed ID: 21045157
[TBL] [Abstract][Full Text] [Related]
18. TGF-β causes Docetaxel resistance in Prostate Cancer via the induction of Bcl-2 by acetylated KLF5 and Protein Stabilization.
Li Y; Zhang B; Xiang L; Xia S; Kucuk O; Deng X; Boise LH; Dong JT
Theranostics; 2020; 10(17):7656-7670. PubMed ID: 32685011
[TBL] [Abstract][Full Text] [Related]
19. Acetyl-11-keto-β-boswellic acid suppresses docetaxel-resistant prostate cancer cells in vitro and in vivo by blocking Akt and Stat3 signaling, thus suppressing chemoresistant stem cell-like properties.
Liu YQ; Wang SK; Xu QQ; Yuan HQ; Guo YX; Wang Q; Kong F; Lin ZM; Sun DQ; Wang RM; Lou HX
Acta Pharmacol Sin; 2019 May; 40(5):689-698. PubMed ID: 30171201
[TBL] [Abstract][Full Text] [Related]
20. Exosomal circRNA Scm-like with four malignant brain tumor domains 2 (circ-SFMBT2) enhances the docetaxel resistance of prostate cancer via the microRNA-136-5p/tribbles homolog 1 pathway.
Tan X; Song X; Fan B; Li M; Zhang A; Pei L
Anticancer Drugs; 2022 Oct; 33(9):871-882. PubMed ID: 36136987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]